Overview
- Breast cancer deaths among women aged 20–49 in the U.S. declined from 9.70 to 1.47 per 100,000 between 2010 and 2020, with the steepest drops after 2016.
- Luminal A breast cancer showed the greatest decline in mortality, but younger women with this subtype had worse 10-year survival rates compared to older women and other subtypes.
- Non-Hispanic Black women experienced the highest mortality rates in 2010 and 2020, with survival outcomes lagging behind other racial and ethnic groups.
- Advances in treatment, including CDK4/6 inhibitors and optimized endocrine therapies introduced after 2015, significantly contributed to improved outcomes for hormone receptor-positive cancers.
- Expanded screening for women aged 40–49 and targeted approaches for high-risk younger women have improved early detection, though access disparities remain a challenge.